0000000000083202

AUTHOR

Alper Sonmez

showing 9 related works from this author

The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.

2015

Background Cardiovascular disease (CVD) risk is substantially increased in subjects with chronic kidney disease (CKD). The Triglycerides (TG) to High-Density Lipoprotein Cholesterol (HDL-C) ratio is an indirect measure of insulin resistance and an independent predictor of cardiovascular risk. No study to date has been performed to evaluate whether the TG/HDL-C ratio predicts CVD risk in patients with CKD. Methods A total of 197 patients (age 53 ± 12 years) with CKD Stages 1 to 5, were enrolled in this longitudinal, observational, retrospective study. TG/HDL-C ratio, HOMA-IR indexes, serum asymmetric dimethyl arginine (ADMA), high sensitivity C-reactive protein (CRP), parathyroid hormone (PT…

AdultMalemedicine.medical_specialtyFlow mediated dilatationTriglyceride to HDL-cholesterol ratioEndocrinology Diabetes and MetabolismAsymmetric dimethyl arginineClinical BiochemistryRenal functionClinical nutritionArginineGastroenterologychemistry.chemical_compoundEndocrinologyInsulin resistanceHigh-density lipoproteinInternal medicineChronic kidney diseasemedicineHumansLongitudinal StudiesRenal Insufficiency ChronicSerum AlbuminTriglyceridesAgedRetrospective StudiesBiochemistry medicalbiologybusiness.industryCholesterolResearchBiochemistry (medical)C-reactive proteinCholesterol HDLMiddle Agedmedicine.diseaseEndocrinologyC-Reactive ProteinchemistryCardiovascular DiseasesParathyroid Hormonebiology.proteinlipids (amino acids peptides and proteins)FemalebusinessBiomarkersKidney diseaseLipidologyGlomerular Filtration RateLipids in health and disease
researchProduct

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

2021

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Dat…

MaleSettore MED/09 - Medicina InternaArterial diseaseCross-sectional studyAdult populationCoronary DiseaseDiseaseGlobal HealthMedical and Health SciencesDoenças Cardio e Cérebro-vascularesAnticholesteremic AgentMonoclonalPrevalenceRegistriesFamilial HypercholesterolemiaHumanizedStroke11 Medical and Health SciencesLS2_9Studies CollaborationAnticholesteremic AgentsGeneral MedicineHeart Disease Risk FactorMiddle AgedFHSC global registry dataEuropeTreatment OutcomeLower prevalenceGuidancelipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Familial hypercholesterolaemiaLife Sciences & BiomedicineHumanAdultmedicine.medical_specialtyCombination therapyFHSC global registry heterozygous familial hypercholesterolaemiaCardiovascular risk factorsAntibodies Monoclonal HumanizedInsightsAntibodiesNOHyperlipoproteinemia Type IIClinicianMedicine General & InternalInternal medicineGeneral & Internal MedicineHealth SciencesmedicineHumansEAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)Cross-Sectional StudieScience & TechnologyGlobal Perspectivebusiness.industryCholesterol LDLmedicine.diseaseCross-Sectional StudiesHeart Disease Risk FactorsHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness
researchProduct

Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease.

2014

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is associated with increased cardiometabolic risk. Although dyslipidemia represents a key factor in this disease, its impact on serum levels of distinct lipoprotein subfractions is largely unknown.OBJECTIVE: To assess the full low-density lipoprotein (LDL) and high-density lipoprotein (I-EDL) profiles in patients with NAFLD.METHODS: Seven LDL and 10 HDL subfractions were assessed by gel electrophoresis (Lipoprint, Quantimetrix Corporation, USA) in men with biopsy proven NAFLD (simple steatosis [n = 17, age, 34 7 years] and nonalcoholic steatohepatitis [NASH; n = 24, age, 32 +/- 6 years]). Exclusion criteria included robust alcohol consump…

AdultMalemedicine.medical_specialtySimple steatosiEndocrinology Diabetes and MetabolismBody Mass Indexchemistry.chemical_compoundHigh-density lipoproteinInsulin resistanceNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseasemedicineInternal MedicineNutrition and DieteticNonalcoholic fatty liver diseaseHumansAspartate AminotransferasesLipoproteinNutrition and Dieteticsbiologybusiness.industryRisk FactorMedicine (all)Fatty livernutritional and metabolic diseasesAspartate AminotransferaseAlanine TransaminaseLipidMiddle Agedmedicine.diseaseAtherosclerosisFatty LiverLipoproteins LDLEndocrinologyAlanine transaminasechemistryAtherosclerosibiology.proteinFemaleNonalcoholic steatohepatitibusinessCardiology and Cardiovascular MedicineLipoproteins HDLBody mass indexDyslipidemiaLipoproteinHumanJournal of clinical lipidology
researchProduct

The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism

2021

ABSTRACT Introduction A number of anti-diabetic treatments have been favored during the continuing spread of the current SARS-CoV-2 pandemic. Glucagon like peptide-1 receptor agonists (GLP1-RAs) are a group of antidiabetic drugs, the glucose reducing effect of which is founded on augmenting glucose-dependent insulin secretion with concomitant reduction of glucagon secretion and delayed gastric emptying. Apart from their glucose lowering effects, GLP1-RAs also exert a plethora of pleiotropic activities in the form of anti-inflammatory, anti-thrombotic and anti-obesogenic properties, with beneficial cardiovascular and renal impact. All these make this class of drugs a preferred option for man…

Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)coronavirusSARS-COV-2PharmacologyIncretinsGlucagonGlucagon-Like Peptide-1 ReceptorAnimalsHumansHypoglycemic AgentsMedicinePharmacology (medical)ReceptorSpecial ReportGlucagon-like peptide 1 receptortherapyPandemicdiabetesSARS-CoV-2business.industrypandemicDiabetesCOVID-19General MedicineGLP-1RAcoronavirus diabetes GLP-1RA pandemic SARS-COV-2 therapy Animals COVID-19Diabetes Mellitus Type 2 Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents Incretins Signal Transduction Treatment OutcomeCOVID-19 Drug TreatmentCoronavirusTreatment OutcomeDiabetes Mellitus Type 2Molecular mechanismbusinessResearch ArticleSignal Transduction
researchProduct

Role of Chemerin in Cardiovascular Diseases.

2022

(1) Background: Obesity is closely connected to the pathophysiology of cardiovascular diseases (CVDs). Excess fat accumulation is associated with metabolic malfunctions that disrupt cardiovascular homeostasis by activating inflammatory processes that recruit immune cells to the site of injury and reduce nitric oxide levels, resulting in increased blood pressure, endothelial cell migration, proliferation, and apoptosis. Adipose tissue produces adipokines, such as chemerin, that may alter immune responses, lipid metabolism, vascular homeostasis, and angiogenesis. (2) Methods: We performed PubMed and MEDLINE searches for articles with English abstracts published between 1997 (when the first re…

adipokinechemerin receptorsMedicine (miscellaneous)610 Medicine & health2701 Medicine (miscellaneous)endothelial dysfunctionGeneral Biochemistry Genetics and Molecular Biologyadipokine cardiovascular disease chemerin chemerin receptors chemerin-targeting therapeutic agents endothelial dysfunction inflammation1300 General Biochemistry Genetics and Molecular Biologycardiovascular diseaseinflammation10209 Clinic for Cardiologychemerin-targeting therapeutic agentschemerinBiomedicines
researchProduct

Critical questions in diabetes management: What are the most compelling challenges and how can we handle them?

2022

Background: The prevalence of diabetes mellitus is growing worldwide, showing almost a 10-fold increase in the last five decades. Despite advances in the understanding of the disease mechanisms, preventive measures, and treatment options, morbidity and mortality remain high. Moreover, the burden of uncontrolled glycemia and associated complications have a significant impact on healthcare costs. To be ready for the future and emerging issues in the management of diabetes and related disorders, a holistic approach is essential for the prevention of the next generations. So many challenges in the management of diabetes exist globally, which differ according to the health infrastructure, and cu…

Internal MedicineDiabetes treatment Diabetogenic environment Health literacy InertiaCardiology and Cardiovascular MedicineInternational Journal of Cardiology Cardiovascular Risk and Prevention
researchProduct

Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL.

2022

Atherosclerosis is responsible for large cardiovascular mortality in many countries globally. It has been shown over the last decades that the reduction of atherosclerotic progression is a critical factor for preventing future cardiovascular events. Low-density lipoproteins (LDL) have been successfully targeted, and their reduction is one of the key preventing measures in patients with atherosclerotic disease. LDL particles are pivotal for the formation and progression of atherosclerotic plaques; yet, they are quite heterogeneous, and smaller, denser LDL species are the most atherogenic. These particles have greater arterial entry and retention, higher susceptibility to oxidation, as well a…

small dense LDL.lipoproteinGeneral MedicineCVDAtherosclerosisresidual risklipoproteinsLipoproteins LDLatherosclerosipreventionRisk FactorsHumansCVD atherosclerosis lipoproteins prevention residual risk small dense LDLlipids (amino acids peptides and proteins)atherosclerosisInsulin Resistancesmall dense LDLDyslipidemiasMedicina (Kaunas, Lithuania)
researchProduct

Betatrophin Levels Are Related to the Early Histological Findings in Nonalcoholic Fatty Liver Disease

2021

Betatrophin, a liver hormone, regulates glucose and lipid metabolism. We investigated the betatrophin levels in nonalcoholic fatty liver disease (NAFLD) and searched for any relationship with histological severity and metabolic parameters. Fifty males with NAFLD [Nonalcoholic Steatohepatitis (NASH) (n = 32)

nonalcoholic fatty liver disease0301 basic medicinemedicine.medical_specialtyBetatrophinEndocrinology Diabetes and Metabolismmedicine.medical_treatmentbetatrophin030209 endocrinology & metabolismMicrobiologydigestive systemBiochemistryArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceinsulin resistanceInternal medicineNonalcoholic fatty liver diseaseMedicineMolecular BiologyBetatrophin Glucose intolerance Insulin resistance Nonalcoholic fatty liver diseaseTriglyceridebusiness.industryInsulinnutritional and metabolic diseasesLipid metabolismmedicine.diseaseQR1-502digestive system diseases030104 developmental biologyEndocrinologyglucose intolerancechemistrySteatosisbusinessHormoneMetabolites
researchProduct

The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart

2021

Nonalcoholic fatty liver disease (NAFLD) is strongly associated to the features of metabolic syndrome which can progress to cirrhosis, liver failure and hepatocellular carcinoma. However, the most common cause of mortality in people with NAFLD is not liver-related but stems from atherosclerotic cardiovascular disease (CVD). The prevalence of NAFLD is on the rise, mainly as a consequence of its close association with two major worldwide epidemics, obesity and type 2 diabetes (T2D). The exact pathogenesis of NAFLD and especially the mechanisms leading to disease progression and CVD have not been completely elucidated. Human fetuin-A (alpha-2-Heremans Schmid glycoprotein), a glycoprotein produ…

Cirrhosisalpha-2-HS-GlycoproteinQH301-705.5030209 endocrinology & metabolismReviewType 2 diabetes030204 cardiovascular system & hematologyBioinformaticsdigestive systemCatalysisInorganic ChemistryPathogenesis03 medical and health sciences0302 clinical medicineInsulin resistanceNon-alcoholic Fatty Liver DiseaseNAFLDNonalcoholic fatty liver diseaseAnimalsHumansMedicineBiology (General)Physical and Theoretical ChemistryQD1-999Molecular BiologyCVD Fetuin‐A NAFLD Animals Cardiovascular Diseases Fibrosis Humans Liver Non-alcoholic Fatty Liver Disease alpha-2-HS-GlycoproteinSpectroscopybusiness.industryOrganic Chemistrynutritional and metabolic diseasesGeneral MedicineCVDmedicine.diseaseFibrosisObesitydigestive system diseasesFetuin-AComputer Science ApplicationsChemistryLiverCardiovascular DiseasesHepatocellular carcinomaMetabolic syndromebusinessInternational Journal of Molecular Sciences
researchProduct